Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Completed · Phase 1

Conditions studied: Melanoma (Skin), Metastatic Cancer

In brief

RATIONALE: Inhaling sargramostim may interfere with the growth of tumor cells and may be an effective treatment for melanoma that has spread to the lung. PURPOSE: This phase I trial is studying the side effects and best dose of inhaled sargramostim in treating patients with melanoma that is metastatic to the lung.

Key facts

Study ID
NCT00017121
Run by
Alliance for Clinical Trials in Oncology
People needed
40
Starts
2002-05-01
Expected to finish
2012-11-01
Last updated by the study team
2016-07-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.